Autopsy report · NCT00522808

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

“Need for re-formulation”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 36 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Arrow Therapeutics

Sponsor type

Industry

Conditions

Chronic Hepatitis C

Interventions

A-831

Participants

36 (planned, not actual)

Sites

3

Countries

New Zealand, United Kingdom

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.